What is the primary purpose of this 10-Q filing?

The primary purpose of this 10-Q filing is to provide investors with an update on Regeneron Pharmaceuticals, Inc.'s financial performance and operational status for the third quarter of 1998, covering the period up to September 29, 1998.

Where can I find the detailed financial information for Regeneron in this filing?

The detailed financial information, including the balance sheet, income statement, and cash flow statement, will be contained within the full 10-Q report. Investors can access this by viewing the '-98-002587.txt' or '-98-002587-index.html' files provided by the SEC's EDGAR system.

What does the filing date and period ending date tell me as an investor?

The filing date of November 4, 1998, indicates when Regeneron officially submitted the report to the SEC. The period ending date of September 29, 1998, specifies the timeframe for which the financial and operational data presented in the report is accurate.

Are there any major announcements or significant events mentioned in the provided filing excerpt?

The provided text is primarily a directory listing from the SEC's EDGAR system and does not contain specific details about major announcements or significant operational events. To find this information, investors must review the actual content of the 10-Q filing itself.

REGN 10-Q Quarterly Report Q3 FY1998 — Revenue, Net Income, EPS

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed its 10-Q for the period ending September 29, 1998. This filing provides a snapshot of the company's financial health and operational status during the third quarter of 1998. While specific financial results and detailed operational updates are not present in the provided directory listing, investors can infer that the company is actively engaged in its reporting obligations. The availability of the filing on the SEC's EDGAR system indicates ongoing corporate activity and transparency, which are crucial for investor confidence.

Key Highlights

1Regeneron Pharmaceuticals, Inc. (REGN) filed its third-quarter 10-Q report on November 4, 1998, for the period ending September 29, 1998.
2The filing is available through the SEC's EDGAR database, indicating ongoing regulatory compliance.
3The report provides essential financial and operational data for investors tracking the company's performance.
4Investors can access further details by reviewing the complete 10-Q filing (.txt or .html formats).
5The filing demonstrates the company's commitment to timely disclosure of material information.
6Key financial metrics and strategic developments will be detailed within the full report.

REGENERON PHARMACEUTICALS, INC. Quarterly Report for Q3 Ended Sep 30, 1998

Summary

Key Highlights

Frequently Asked Questions